Latest SGMT stock forecast numbers reveal steady EPS growth projections, now averaging $1.35 by year-end. This aligns with stronger export sales volumes in core semiconductor segments and stable pricing contracts. Lastly, Sagimet is exploring denifanstat as a treatment for the aggressive brain cancer glioblastoma, specifically recurrent glioblastoma multiforme (rGBM), in combination with bevacizumab. Phase 2 data of this combination therapy met the primary endpoint of progression-free survival (PFS), with a 31.4% six-month PFS compared to 16% for bevacizumab monotherapy. The Phase 3 trial, like the acne study, is being conducted in China with Ascletis, with topline data expected in the first half of 2025. Our video reports and analysis, with early access to exclusive, subscriber-only videos SGMT stock forecast sentiment benefits from reduced supply chain constraints. A 3.2% improvement in operating margins is forecast for FY2024, driven by automation and energy efficiency upgrades across facilities.